- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Budenheim 
Captisol 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Budenheim Captisol Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma
Enhanced Breast Cancer Therapy using TPGS-Functionalized PLGA Nanoparticles: a 3D Spheroid Tumor Model Approach
Enhanced Breast Cancer Therapy using TPGS-Functionalized PLGA Nanoparticles
Abstract
A d-α-Tocopheryl Polyethylene Glycol-1000 Succinate (TPGS)-functionalized nanoparticle formulation was developed for the co-delivery of Paclitaxel (PTX) and Gefitinib (GEF) to achieve synergistic therapeutic efficacy against triple-negative breast cancer (TNBC). To determine the optimal drug ratio, multiple PTX: GEF combinations were evaluated in MDA-MB-231 TNBC cells. Among the tested ratios, 0.72:0.25 (w/w) demonstrated the most pronounced cytotoxic response, with a combination index (CI) of 0.547, confirming a strong synergistic interaction between PTX and GEF. Co-loaded nanoparticles were prepared using the single emulsion solvent evaporation method and surface-functionalized with TPGS to enhance cellular uptake, stability, and therapeutic performance.
Highlights
- TPGS-functionalized nanoparticles enhance PTX and GEF synergy for TNBC treatment.
- A PTX: GEF ratio of 0.75: 0.25 was found to be optimal for maximum synergy.
- Nanoparticles showed good stability and high entrapment with sustained release.
- Enhanced cellular uptake and cytotoxicity exhibited in MDA-MB-231 cells.
- 3D spheroid studies show 2.8-fold volume reduction with improved penetration.
The TPGS-functionalized co-loaded nanoparticles exhibited a mean particle size of 246.7 ± 4.5 nm, a PDI of 0.28 ± 0.03, and a zeta potential of − 21.6 ± 2.8 mV, with high entrapment efficiencies of 87.3 ± 3.4% for PTX and 80.5 ± 2.9% for GEF. In cellular uptake studies, TPGS-functionalized co-loaded nanoparticles achieved 2.87-fold higher internalization in MDA-MB-231 cells compared to free drugs, resulting in the lowest IC50 (0.87 ± 0.38 µg/mL) among all formulations. Furthermore, 3-D spheroid experiments demonstrated enhanced penetration and therapeutic efficiency, yielding a 2.8-fold reduction in spheroid volume from Day 0 to Day 8 (147.38 ± 12.33 mm3 to 50.09 ± 3.87 mm3).
Overall, these findings indicate that the optimized PTX: GEF ratio, delivered via TPGS-functionalized nanoparticles, facilitates enhanced cellular uptake, potent cytotoxicity, and improved tumor penetration, representing a promising strategy for synergistic and targeted therapy in aggressive TNBC.
Continue reading here
Yadav, K.S. Enhanced Breast Cancer Therapy using TPGS-Functionalized PLGA Nanoparticles: a 3D Spheroid Tumor Model Approach. J Clust Sci 36, 235 (2025). https://doi.org/10.1007/s10876-025-02957-1
See also the interesting video on Vitamin E TPGS below and read more: here
Related Posts
